Aadi Bioscience (STU:3350) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Debt-to-Equity?

Aadi Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.39 Mil. Aadi Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.68 Mil. Aadi Bioscience's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €83.22 Mil. Aadi Bioscience's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aadi Bioscience's Debt-to-Equity or its related term are showing as below:

STU:3350' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.83 Med: 0.01 Max: 0.02
Current: 0.01

During the past 4 years, the highest Debt-to-Equity Ratio of Aadi Bioscience was 0.02. The lowest was -0.83. And the median was 0.01.

STU:3350's Debt-to-Equity is ranked better than
99.91% of 1063 companies
in the Biotechnology industry
Industry Median: 0.15 vs STU:3350: 0.01

Aadi Bioscience Debt-to-Equity Historical Data

The historical data trend for Aadi Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Debt-to-Equity Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

-0.83

0.01

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial										0.01	0.01	0.01	0.01	0.01

Competitive Comparison of Aadi Bioscience's Debt-to-Equity

For the Biotechnology subindustry, Aadi Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aadi Bioscience's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's Debt-to-Equity falls into.

Aadi Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aadi Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.398	+	0.764)	/	96.464
	=	0.01

Aadi Bioscience's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.391	+	0.679)	/	83.223
	=	0.01

Aadi Bioscience (STU:3350) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aadi Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (STU:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (STU:3350) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AADI:USA

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (STU:3350) Headlines

No Headlines